Baraclude Bests Hepsera On Viral Load Reduction In HBV Patients – Bristol Study
Study shows that 58 percent of Baraclude-treated patients achieved undetectable viral load at 48 weeks versus 19 percent taking adefovir.
Study shows that 58 percent of Baraclude-treated patients achieved undetectable viral load at 48 weeks versus 19 percent taking adefovir.